Fairlead Tactical Sector ETF (TACK) Historical

St George Mining Ltd executive chairman John Prineas talked with Kerry Stevenson at Proactive about the company's recent acquisition of the Araxá niobium and rare earths project in Brazil. The deal, completed in February, provides St George with an advanced-stage project with high-grade niobium and rare earth elements. Prineas highlighted niobium’s strategic importance, noting that it is primarily used to strengthen steel, with additional applications in medical technology, batteries, and defence. He emphasised the commodity's stable pricing due to limited global supply. The company secured A$20 million in funding to advance the project and is preparing a JORC-compliant mineral resource estimate, expected in the coming weeks. The existing data, based on historical drilling, indicates a 20-year mine life and a US$956 million NPV under a previous non-JORC study. St George aims to optimise the project for niobium, conduct further drilling, and expand the resource. Prineas also addressed Brazil's mining jurisdiction, highlighting strong government support and agreements to expedite approvals. The company is pursuing a dual-track strategy, progressing toward development while ramping up exploration drilling to expand the resource base. Stay tuned for more updates! Visit Proactive's YouTube channel for more interviews, and don’t forget to like, subscribe, and turn on notifications. #StGeorgeMining #ASXSGQ #Niobium #RareEarths #MiningStocks #JORC #BrazilMining #CriticalMetals #ResourceInvestment #BatteryMetals

Imugene Ltd CEO Leslie Chong talked with Kerry Stevenson at Proactive about the FDA's fast-track designation for its immunotherapy candidate, Azercell. The therapy, an allogeneic off-the-shelf CAR-T treatment, has shown promising results in patients with diffuse large B-cell lymphoma (DLBCL), a highly aggressive form of blood cancer. Chong highlighted that four out of seven patients treated with Azercell achieved complete response, meaning their cancer was no longer detectable. The longest response duration has now exceeded 11 months. “The FDA has recognised the importance of a product like this and has given us fast-track designation,” Chong stated. The FDA's fast-track status allows Imugene to expedite regulatory discussions and move towards potential commercialization more efficiently. The company sees this as a critical milestone, with Chong emphasising that the priority now is gathering sufficient data to advance towards registration studies. With an estimated 80,000 new DLBCL cases diagnosed annually in the US, Azercell could address a significant unmet need, especially for patients who have exhausted other treatment options. For more updates on Imugene and other biotech innovations, visit Proactive’s YouTube channel. Don't forget to like this video, subscribe, and enable notifications for future content. #Imugene #Biotech #CancerResearch #FDA #CAR_T #Oncology #BloodCancer #DLBCL #MedicalBreakthrough #FastTrack #Immunotherapy

Anthony Ginsberg, CEO of GinsGlobal Index Fund, recently spoke with Steve Darling from Proactive to discuss the structure, performance, and strategic advantages of the GinsGlobal Tech Megatrend ETF. He highlighted three core strengths of the fund: its equally weighted structure, international diversification, and targeted exposure to high-growth technology sectors such as AI, robotics, cloud computing, and cybersecurity. Unlike traditional Nasdaq-style funds that are often dominated by a few large-cap stocks, the Tech Megatrend ETF avoids over-concentration, with its largest holdings representing only about 9% of the total portfolio weight. The fund also offers broad international exposure, with 60% of holdings based in the U.S., 10% in China, and approximately 20% across broader Asia. This balanced approach extends across eight key subthemes, including digital entertainment, gene therapy, and social media. The ETF has delivered a 17% return over the past year, with strong performance from companies such as BYD and Alibaba. Ginsberg noted that major mergers and acquisitions in the tech sector, including Microsoft’s $72 billion Activision deal and Google Cloud’s expansion into cybersecurity, are further driving momentum. He also pointed to reshoring trends that are benefiting automation and AI-driven businesses, positioning the fund to capitalize on these market shifts. In terms of valuation, Ginsberg emphasized that the ETF maintains an average price-to-earnings ratio of 18 to 19 times future earnings, which he considers reasonable compared to historical tech market bubbles. Ginsberg concluded by highlighting the increasing role of AI in digital entertainment and the ongoing convergence of major tech trends within the ETF’s portfolio. With its diversified, forward-looking investment strategy, the GinsGlobal Tech Megatrend ETF continues to present a compelling opportunity for investors seeking exposure to the next wave of technological innovation. #TechMegatrendETF,

Protalix BioTherapeutics Chairman Dr Eliot Forster joined Steve Darling from Proactive to discuss the company’s innovative approach to drug manufacturing, which leverages plant cells instead of traditional mammalian cells. This unique method enhances purity, sustainability, and reproducibility, setting Protalix apart in the biotech industry. Forster highlighted the company's commercial success, noting that Protalix has two marketed products through partnerships with Pfizer and Chiesi. He emphasized the company’s strong financial position, having repaid all outstanding debt and operating without warrants, reinforcing its ability to drive long-term growth. A key focus of the discussion was PRX-115, Protalix’s experimental treatment for severe gout. In 2024, the company completed a first-in-human study with promising results. A Phase 2 trial is scheduled for 2025, and Forster expressed optimism about its potential to address a significant unmet medical need. Beyond PRX-115, Forster detailed the company’s strong financial performance in 2024, describing it as a breakthrough year fueled by increased revenue from its three business streams. Looking ahead, Protalix is actively advancing treatments for rare diseases, including renal conditions, as it continues to expand its innovative pipeline. #proactiveinvestors #protalixbiotherapeutics #nyseamerican #plx #Biotech #DrugDevelopment #GoutTreatment #Pharmaceuticals #EliotForster #PRX115 #HealthcareInnovation #ProactiveInvestors